Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Entyvio (vedolizumab) and Entocort EC (budesonide) are both used to treat Crohn's disease, but they work in different ways and are used for different severities of the condition. Entyvio is a biologic medication known as an integrin antagonist, which is given either as an intravenous infusion or a subcutaneous injection. It is used for moderate-to-severe Crohn's disease and works by reducing the activity of immune cells to lower inflammation. On the other hand, Entocort EC is a corticosteroid taken orally and is used for mild-to-moderate Crohn's disease. It works by reducing inflammation directly in the intestines. Entyvio can cause serious side effects like infusion reactions and infections, while Entocort EC might lead to weight gain, infections, and other steroid-related side effects. Entocort EC is available as a lower-cost generic, whereas Entyvio does not have a generic form.
Entyvio (vedolizumab)
Budesonide
Entyvio (vedolizumab)
Budesonide
Summary of Entyvio vs. Entocort
Summary for Integrin antagonist
Prescription only
Entyvio, the brand name for vedolizumab, is an injection used to treat ulcerative colitis (UC) and Crohn's disease (CD) in adults. It belongs to a drug class called integrin antagonists that helps lower inflammation in the gut. Entyvio (vedolizumab) is an infusion that's given through the vein by a healthcare professional. After the first 2 doses, it's usually given every 2 months. If it works well, people can switch to injections under the skin every 2 weeks using prefilled syringes or pens. Side effects include headache, mild infections, and joint pain.
Summary for Corticosteroid
Prescription only
Budesonide is a corticosteroid that's used to treat mild-to-moderate Crohn's disease in adults and children. It's available as capsules that are taken by mouth once daily. The most common side effects are headache and respirator infections. More rarely, it might cause weight gain too.